{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T18:09:24Z","timestamp":1657908564237},"reference-count":12,"publisher":"Institute of Biochemistry","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>A selective prolyl endopeptidase (PEP) inhibitor benzyloxycarbonyl-prolyl-prolinal (IC50 = 1,61\u00b10,12 nmol\/l)  and a nonselective PEP inhibitor benzyloxycarbonyl-methionyl-cyanopyrrolidine (IC50 = 2,01\u00b10,14 nmol\/l) exhibit  a comparable antiexudative effect at single doses of 2 mg\/kg and 5 mg\/kg (intraperitoneally) in outbred mice with  peritonitis induced by 1% acetic acid. However, only benzyloxycarbonyl-methionyl-cyanopyrrolidine at a dose  of 5 mg\/kg reduces acetic acid induced pain in animals.<\/jats:p>","DOI":"10.18097\/pbmc20206605423","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T11:55:46Z","timestamp":1604404546000},"page":"423-426","source":"Crossref","is-referenced-by-count":1,"title":["Comparative effect of the prolyl endopeptidase inhibitors, benzyloxycarbonyl-prolyl-prolinal and benzyloxycarbonyl-methionyl-cyanopyrrolidine, on the acute exudative inflammation and visceral pain in mice"],"prefix":"10.18097","volume":"66","author":[{"given":"E.A.","family":"Ivanova","sequence":"first","affiliation":[{"name":"Zakusov Institute of Pharmacology, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.N.","family":"Zolotov","sequence":"additional","affiliation":[{"name":"Zakusov Institute of Pharmacology, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.A.","family":"Voronina","sequence":"additional","affiliation":[{"name":"Zakusov Institute of Pharmacology, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7443","published-online":{"date-parts":[[2020]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Polgar L. (1994) Methods Enzymol., 244, 188-200.","DOI":"10.1016\/0076-6879(94)44016-6"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Gaggar A., Jackson P.L., Noerager B.D., O\u2019Reilly P.J., McQuaid D.B., Rowe S.M., Clancy J.P., Blalock J.E. (2008) J. Immunol., 180(8), 5662-5669.","DOI":"10.4049\/jimmunol.180.8.5662"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Henson P.M., Vandivier R.W. (2006) Nat. Med., 12(3), 280-281.","DOI":"10.1038\/nm0306-280"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Penttinen A., Tenorio-Laranga J., Siikanen A., Morawski M., Ro\u00dfner S., Garcia-Horsman J.A. (2011) CNS Neurol. Disord. Drug Targets, 10(3), 340-348.","DOI":"10.2174\/187152711794653742"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Tenorio-Laranga J., Coret-Ferrer F., Casanova-Estruch B., Burgal M., Garcia-Horsman J.A. (2010) J. Neuroinflammation, 7, Article number: 23.","DOI":"10.1186\/1742-2094-7-23"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Hashimoto Y., Kakegawa H., Narita Y., Hayakawa T., Kos J., Turk V., Katunuma N. (2001) Biochem. Biophys. Res. Commun., 283(2), 334-339.","DOI":"10.1006\/bbrc.2001.4787"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Rasoul S., Carretero O.A., Peng H., Cavasin M.A., Zhuo J., Sanchez-Mendoza A., Brigstock D.R., Rhaleb N.E. (2004) J. Hypertens., 22(3), 593-603.","DOI":"10.1097\/00004872-200403000-00023"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Bondarenko N.S., Shneiderman A.N., Guseva A.A., Umarova B.A. (2017) Acta Naturae, 9(1), 52-55.","DOI":"10.32607\/20758251-2017-9-1-52-55"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Natunen T.A., Gynther M. Rostalski H., Jaako K., Jalkanen A. (2019) Basic Clin. Pharmacol. Toxicol., 124(1), 40-49.","DOI":"10.1111\/bcpt.13094"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Ivanova E.A., Zolotov N.N., Pozdnev V.F., Voronina T.A. (2020) Biomeditsinskaya Khimiya, 66(1), 77-82.","DOI":"10.18097\/pbmc20206601077"},{"key":"ref11","unstructured":"Guidance on preclinical study of new pharmacological substances. Part 1. (2012) Grif and K, Moscow, 944 p."},{"key":"ref12","unstructured":"Ivanova E.A., Zolotov N.N., Pozdnev V.F., Voronina T.A. (2018) Patogenez, 16(1), 51-57."}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T11:59:22Z","timestamp":1604404762000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2020-66-5-423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020]]},"published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmc20206605423","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}